Akari Therapeutics Plc
AKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001541157
No open-market purchases or sales by Akari Therapeutics Plc insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 9
- 13F valueReported value at the end of Q2 2026
- $1.54M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AKTX, Q2 2026
No superinvestor reported holding AKTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Akari Therapeutics Plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 (view filing)5:00 PM ET | Dec 16, 2025 | 90 daysLate | Neal James RDirector | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +11.1K | $0.4041 | +$2.25K | –3.09K after | Derivative4 lots |
| Dec 18, 2025 (view filing)9:58 PM ET | Dec 16 | 2 days | Prudo-Chlebosz RaymondDirector | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +2.01M | $0.4041 | +$406.2K | –386.7K after | Derivative4 lots |
| Dec 18, 2025 (view filing)9:57 PM ET | Dec 16 | 2 days | Patel Sandip IDirector | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +804.3K | $0.4041 | +$162.5K | –154.7K after | Derivative4 lots |
| Dec 18, 2025 (view filing)9:57 PM ET | Dec 16 | 2 days | Huh HoyoungDirector, 10% Owner | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +7.42M | $0.4041 | +$1.50M | –3.09M after | Derivative4 lots |
| Dec 18, 2025 (view filing)9:57 PM ET | Dec 16 | 2 days | Farag Kameel D.Interim CFO | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +49.5K | $0.4041 | +$10.0K | –24.7K after | Derivative2 lots |
| Dec 18, 2025 (view filing)9:56 PM ET | Dec 16 | 2 days | Patel Samir RashmikantDirector, 10% Owner | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +1.24M | $0.4041 | +$250.0K | –618.7K after | Derivative2 lots |
| Dec 18, 2025 (view filing)9:56 PM ET | Dec 16 | 2 days | Patel Samir RashmikantDirector, 10% Owner | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +464.0K | $0.4041 | +$93.7K | –232.0K after | Derivative2 lots |
| Dec 18, 2025 (view filing)9:56 PM ET | Dec 16 | 2 days | Gaslightwala AbizerCEO | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +2.17M | $0.4041 | +$437.5K | –773.3K after | Derivative4 lots |
| Dec 18, 2025 (view filing)9:56 PM ET | Dec 16 | 2 days | Bazemore Robert BDirector | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +309.3K | $0.4041 | +$62.5K | –30.9K after | Derivative4 lots |
| Aug 29, 2025 (view filing) | Aug 21-25 | 8 daysLate | Gaslightwala AbizerCEO | PPurchaseAmerican Depositary Shares representing Ordinary Shares | +21.0K | $0.9305 | +$19.5K | +7.6%298.6K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Akari Therapeutics Plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MMCAP International Inc. SPC | 100,000 | $1.02M | 0.09% | +100,000 | New |
| Cresset Asset Management, LLC | 20,561 | $210.6K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 15,463 | $158.4K | 0.00% | +15,463 | New |
| HRT Financial LP | 13,745 | $140.0K | 0.00% | +13,745 | New |
| IFP Advisors, Inc | 181 | $1.85K | 0.00% | −7,250−97.6% | Reduced |
| SBI Securities Co., Ltd. | 14 | $143 | 0.00% | +9+180.0% | Added |
| Caitong International Asset Management Co., Ltd | 8 | $82 | 0.00% | +8 | New |
| Northwestern Mutual Wealth Management Co | 7 | $72 | 0.00% | +7 | New |
| Truvestments Capital LLC | 1 | $10 | 0.00% | 00.0% | Unchanged |